ARQT
Arcutis Biotherapeutics, Inc.Company Information
- Company Name
- Arcutis Biotherapeutics, Inc.
- CIK
- CIK0001787306
- Category
- Large accelerated filer
- Ticker: Exchange
- ARQT: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ARQT
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-06-13
- Last sale
- 2026-09-16
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 636,213
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 130,581,929
- Shares outstanding
- 130,522,000
- Ownership
- 100.05%
Earnings Market Reaction
- Filing date
- 2026-08-05
- Price on filing date
- —
- 1-month reaction
- -12.25%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents Fair Value Disclosure | 34 | 35 | 43 | 47 | 73 | 53 | 71 | 135 | 84 | 190 | 88 | 107 | ||||||
| Restricted Cash And Cash Equivalents | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Available For Sale Securities Debt Securities Current | 204 | 189 | 178 | 144 | 118 | 145 | 157 | 196 | 278 | 214 | 183 | 120 | ||||||
| Accounts Receivable Net Current | 155 | 144 | 146 | 115 | 107 | 85 | 73 | 60 | 43 | 37 | 26 | 19 | ||||||
| Inventory Net | 39 | 37 | 23 | 22 | 16 | 17 | 15 | 14 | 14 | 13 | 13 | 14 | ||||||
| Prepaid Expense And Other Assets Current | 35 | 32 | 21 | 20 | 19 | 23 | 20 | 18 | 14 | 13 | 19 | 20 | ||||||
| Assets Current | 468 | 438 | 411 | 349 | 333 | 324 | 336 | 424 | 435 | 468 | 330 | 282 | ||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | ||||||
| Intangible Assets Net Excluding Goodwill | 14 | 14 | 15 | 15 | 16 | 17 | 9 | 10 | 6 | 6 | 6 | 7 | ||||||
| Operating Lease Right Of Use Asset | 4 | 4 | 4 | 5 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Other Assets Noncurrent | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets | 489 | 460 | 433 | 371 | 352 | 344 | 349 | 437 | 445 | 479 | 341 | 293 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 7 | 18 | 13 | 6 | 15 | 25 | 14 | 19 | 8 | 13 | 12 | 13 | ||||||
| Long Term Debt Current | 7 | 8 | 1 | 1 | 1 | - | 0 | 100 | - | - | - | - | ||||||
| Accrued Liabilities Current | 147 | 137 | 116 | 93 | 88 | 66 | 67 | 53 | 43 | 34 | 34 | 28 | ||||||
| Operating Lease Liability Current | - | - | 0 | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities Current | 160 | 163 | 130 | 100 | 104 | 91 | 81 | 172 | 51 | 47 | 47 | 42 | ||||||
| Operating Lease Liability Noncurrent | 5 | 5 | 5 | 5 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 4 | ||||||
| Long Term Debt Noncurrent | 102 | 101 | 108 | 107 | 107 | 108 | 107 | 105 | 204 | 203 | 202 | 201 | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | - | ||||||
| Liabilities | 268 | 270 | 243 | 213 | 213 | 201 | 191 | 281 | 258 | 254 | 253 | 246 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 1,356 | 1,340 | 1,328 | 1,314 | 1,302 | 1,290 | 1,279 | 1,267 | 1,256 | 1,242 | 1,071 | 963 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -1 | -0 | -0 | -0 | -0 | -0 | 1 | -0 | -0 | 0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -1,134 | -1,149 | -1,138 | -1,155 | -1,163 | -1,147 | -1,122 | -1,111 | -1,070 | -1,017 | -982 | -916 | ||||||
| Stockholders Equity | 221 | 190 | 189 | 158 | 139 | 143 | 158 | 157 | 186 | 225 | 89 | 47 | ||||||
| Liabilities And Stockholders Equity | 489 | 460 | 433 | 371 | 352 | 344 | 349 | 437 | 445 | 479 | 341 | 293 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | ||||||
| Common Stock Shares Issued | 126 | 125 | 123 | 120 | 120 | 119 | 118 | 117 | 116 | 116 | 97 | 62 | ||||||
| Preferred Stock Shares Authorized | - | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Shares Outstanding | 126 | 125 | 123 | 120 | 120 | 119 | 118 | 117 | 116 | 116 | 97 | 62 | ||||||
| Preferred Stock Shares Outstanding | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialArcutis Biotherapeutics, Inc. (ARQT) — SEC Financial Statements & Analysis
Arcutis Biotherapeutics, Inc. (ARQT) is a pharmaceutical preparations company, incorporated in DE. Arcutis Biotherapeutics, Inc. trades on Nasdaq as: ARQT. Arcutis Biotherapeutics, Inc. (ARQT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, Arcutis Biotherapeutics, Inc. carries a market cap of $3.42B, a P/E ratio of 120.00x, a P/B ratio of 15.52x, a P/S ratio of 7.41x, an enterprise value of $3.50B, and an EV/EBITDA multiple of 89.84x. On profitability, it posts a gross margin of 91.10%, an operating margin of 7.41%, a net margin of 6.17%, a Return on Equity (ROE) of 15.86%, a Return on Assets (ROA) of 6.78%, and a Return on Invested Capital (ROIC) of 13.79%. Per share, it reports EPS of $0.22, diluted EPS of $0.21, free cash flow per share of $0.30, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 78.05% year-over-year, net income growth of -130.58% year-over-year, and EPS growth of -129.75% year-over-year. On the balance sheet, it maintains a current ratio of 2.92x, a quick ratio of 2.46x, working capital of $307.33M, a debt-to-equity ratio of 1.21x, a debt ratio of 0.55, an interest coverage ratio of 2.47x, free cash flow of $39.15M (TTM), and net debt of $74.47M. Figures sourced from SEC EDGAR.
- Market Cap
- $3.42B
- P/E TTM
- 120.00x
- EPS TTM
- $0.22
- P/B TTM
- 15.52x
- ROE TTM
- 15.86%
- ROA TTM
- 6.78%
- Debt To Equity
- 1.21x
- Free Cash Flow TTM
- $39.15M
- Net Revenue TTM Growth 1Y
- 78.05%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Arcutis Biotherapeutics, Inc. in?
Arcutis Biotherapeutics, Inc. (ARQT) operates in the Pharmaceutical Preparations industry.
What exchange does ARQT trade on?
Arcutis Biotherapeutics, Inc. (ARQT) trades on the Nasdaq.
Where is Arcutis Biotherapeutics, Inc. incorporated?
Arcutis Biotherapeutics, Inc. is incorporated in DE.
When was Arcutis Biotherapeutics, Inc. (ARQT)'s most recent SEC filing?
Arcutis Biotherapeutics, Inc. (ARQT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05.
What is ARQT's market cap?
Arcutis Biotherapeutics, Inc. (ARQT) has a market capitalization of $3.42B as of 2026-06-30.
What is ARQT's P/E ratio?
Arcutis Biotherapeutics, Inc. (ARQT)'s trailing twelve month P/E ratio is 120.00x as of 2026-06-30.
What is ARQT's EPS (earnings per share)?
Arcutis Biotherapeutics, Inc. (ARQT)'s trailing twelve month EPS is $0.22 as of 2026-06-30.
What is ARQT's ROE (return on equity)?
Arcutis Biotherapeutics, Inc. (ARQT)'s trailing twelve month Return on Equity (ROE) is 15.86% as of 2026-06-30.
What is ARQT's ROA (return on assets)?
Arcutis Biotherapeutics, Inc. (ARQT)'s trailing twelve month Return on Assets (ROA) is 6.78% as of 2026-06-30.
What is ARQT's ROIC (return on invested capital)?
Arcutis Biotherapeutics, Inc. (ARQT)'s trailing twelve month Return on Invested Capital (ROIC) is 13.79% as of 2026-06-30.
What is ARQT's EV/EBITDA?
Arcutis Biotherapeutics, Inc. (ARQT)'s trailing twelve month EV/EBITDA is 89.84x as of 2026-06-30.